1226548-19-1

Basic information

• Product Name: (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol
• Synonyms: (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol
• CAS NO: 1226548-19-1
• Molecular Weight: 326.422
• Mol File: 1226548-19-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol(1226548-19-1)
• EPA Substance Registry System: (S)-2-phenyl-2-((5,6,7,8-tetrahydropyrido[4’,3’:4,5]thieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol(1226548-19-1)

Safety Data

• Hazardous Substances Data: 1226548-19-1(Hazardous Substances Data)

Upstream product

• 20989-17-7 (2S)-2-phenylglycinol 
• 1226548-17-9 tert-butyl (S)-4-((2-hydroxy-1-phenylethyl)amino)-5,8-dihydropyrido[4’,3’:4,5]thieno[2, 3-d]pyrimidine-7(6H)carboxylate 
• 946198-89-6 tert-butyl 4-chloro-5,6-dihydropyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate 
• 874801-60-2 tert-butytert-butyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno-[2,3-d]pyrimidine-7-carboxylatel-4-oxo-3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno-[2,3-d]pyrimidine-7-carboxylate 
• 193537-14-3 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3,6-dicarboxylic acid 6-tert-butyl ester 3-ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1226548-20-4 1-(4-(((1S)-2-hydroxy-1-phenylethyl)amino)-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-propen-1-one 
• 1226548-21-5 1-(4-[(1S)-2-hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-1-propanone 
• 1226548-24-8 1-(4-[(1S)-2-hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-butyn-1-one 

Relevant articles and documents

PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy

Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR-TKIs) are used as molecular targeted therapy for non-small cell lung cancer (NSCLC) patients. The therapy is applied to the patients having EGFR-primary L858R mutation, but drug toleran

Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and michael acceptor group for maximal potency

HTS hit 7 was modified through hybrid design strategy to introduce a chiral side chain followed by introduction of Michael acceptor group to obtain potent EGFR kinase inhibitors 11 and 19. Both 11 and 19 showed over 3 orders of magnitude enhanced HCC827 a